SCHEMBL1603891

SCHEMBL1603891

O=C(/C=C/c1c(O)cc(O)cc1O)c1ccc(O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.67
F3 P13726 2/20 0.61
ABCG2 Q9UNQ0 1/20 0.60
MAPT P10636 5/20 0.56
KMT2A Q03164 5/20 0.56
CYP3A4 P08684 3/20 0.56
MAOB P27338 3/20 0.56
MEN1 O00255 2/20 0.56
MAOA P21397 2/20 0.56
HSPD1 P10809 2/20 0.56
HSPE1 P61604 2/20 0.56
ALDH2 P05091 1/20 0.56
CYP19A1 P11511 1/20 0.56
CYP1B1 Q16678 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
XDH P47989 1/20 0.56
TYR P14679 1/20 0.54
ALDH1A1 P00352 1/20 0.53
RAB9A P51151 2/20 0.53
ESR1 P03372 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200343 0.87 TYR (0.66) CHRNA7F3ABCG2MAPTKMT2A
SCHEMBL2200345 0.87 TYR (0.66) CHRNA7F3ABCG2MAPTKMT2A
SCHEMBL11343154 0.85 ABCG2 (0.70) CHRNA7F3ABCG2MAPTKMT2A
SCHEMBL28695326 0.85 CTSL (0.66) CHRNA7ABCG2MAOBMAOATDP1
SCHEMBL28695325 0.85 CTSL (0.66) CHRNA7ABCG2MAOBMAOATDP1
SCHEMBL9341548 0.84 MAPT (0.64) CHRNA7MAPTKMT2AMEN1ALDH1A1
SCHEMBL9341540 0.84 MAPT (0.64) CHRNA7MAPTKMT2AMEN1ALDH1A1
SCHEMBL676965 0.80 CYP3A4 (0.70) CHRNA7ABCG2MAPTKMT2ACYP3A4
SCHEMBL1695381 0.80 CHRNA7 (1.00) CHRNA7F3TDP1TYRCAPN1
SCHEMBL21446884 0.80 CHRNA7 (1.00) CHRNA7F3TDP1TYRCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242144-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases RESVERLOGIX CORP. 2011-04-07 US disclosed
US-7846915-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2010-12-07 US disclosed
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045010-A2 STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases APOB, APOL1, HDLBP CHRNA7 3919/4885F3 671/4885ABCG2 1177/4885
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases APOB, APOL1, HDLBP CHRNA7 3919/4885F3 671/4885ABCG2 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.